

## DAFTAR PUSTAKA

- Abd Hamid, M. *et al.* (2019) "Enriched HLA-E and CD94/NKG2A interaction limits antitumor CD8<sup>+</sup> tumor-infiltrating T lymphocyte responses," *Cancer immunology research*. AACR, 7(8), hal. 1293–1306.
- Ali, Z., Yousaf, N. dan Larkin, J. (2013) "Melanoma epidemiology, biology and prognosis.," *EJC supplements: EJC: official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]*. England, 11(2), hal. 81–91. doi: 10.1016/j.ejcsup.2013.07.012.
- Antohe, M. *et al.* (2019) "Tumor infiltrating lymphocytes: The regulator of melanoma evolution.," *Oncology letters*. Greece, 17(5), hal. 4155–4161. doi: 10.3892/ol.2019.9940.
- Arrangoiz, R. *et al.* (2016) "Melanoma Review: Epidemiology, Risk Factors, Diagnosis and Staging.," *Journal of Cancer Treatment and Research*, 4(1), hal. 1–15.
- Battin, C. *et al.* (2022) "NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E," *Immunology*. Wiley Online Library, 166(4), hal. 507–521.
- Borst, L. *et al.* (2022) "NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division," *International Journal of Cancer*. John Wiley & Sons, Ltd, 150(4), hal. 688–704. doi: <https://doi.org/10.1002/ijc.33859>.
- Borst, L., van der Burg, S. H. dan van Hall, T. (2020) "The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment.," *Clinical cancer research: an official journal of the American Association for Cancer Research*. United States, 26(21), hal. 5549–5556. doi: 10.1158/1078-0432.CCR-19-2095.
- Bossard, C. *et al.* (2012) "HLA-E/ $\beta$ 2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression.," *International journal of cancer*. United States, 131(4), hal. 855–863. doi: 10.1002/ijc.26453.
- Brummel, K. *et al.* (2023) "Tumour-infiltrating lymphocytes: from prognosis to treatment selection," *British Journal of Cancer*, 128(3), hal. 451–458. doi: 10.1038/s41416-022-02119-4.
- del Campo, A. B. *et al.* (2012) "Targeting HLA class I expression to increase tumor immunogenicity," *Tissue antigens*. Wiley Online Library, 79(3), hal. 147–154.
- Cancer Research UK (2023) *Melanoma skin cancer incidence statistics*. Tersedia pada: 2023.
- Carrega, P. *et al.* (2009) "Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells," *PLoS One*. Public Library of Science San Francisco, USA, 4(12), hal. e8132.
- Cree, I. A. *et al.* (2021) "Counting mitoses: SI(ze) matters!," *Modern Pathology*, 34(9), hal. 1651–1657. doi: 10.1038/s41379-021-00825-7.
- Creelan, B. C. dan Antonia, S. J. (2019) "The NKG2A immune checkpoint - a new direction in cancer immunotherapy.," *Nature reviews. Clinical*

- oncology*. England, 16(5), hal. 277–278. doi: 10.1038/s41571-019-0182-8.
- D’Aguanno, S. *et al.* (2021) “Hypoxia-dependent drivers of melanoma progression,” *Journal of experimental & clinical cancer research : CR*. England, 40(1), hal. 159. doi: 10.1186/s13046-021-01926-6.
- Derré, L. *et al.* (2006) “Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells,” *Journal of immunology (Baltimore, Md. : 1950)*. United States, 177(5), hal. 3100–3107. doi: 10.4049/jimmunol.177.5.3100.
- Donley, G. M. *et al.* (2019) “Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States,” *British journal of cancer*. England, 120(7), hal. 754–760. doi: 10.1038/s41416-019-0411-z.
- Ducoin, K. *et al.* (2022) “Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer,” *Oncoimmunology*. United States, 11(1), hal. 2046931. doi: 10.1080/2162402X.2022.2046931.
- Eugène, J. *et al.* (2020) “The inhibitory receptor CD94/NKG2A on CD8(+) tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLA-E/β2m overexpression,” *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.* United States, 33(3), hal. 468–482. doi: 10.1038/s41379-019-0322-9.
- F. Kratochvill, G. Neale, J. Haverkamp, L.-A. Van de Velde, A. Smith, D. Kawauchi, J. McEvoy, M. Roussel, M. Dyer, J. Qualls, P. Murray, TNF counterbalances the emergence of M2 tumor macrophages, *Cell Rep.* 12 (11) (2015) 1902–1914.
- Falahat, R. *et al.* (2019) “STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity,” *Cancer immunology research*. United States, 7(11), hal. 1837–1848. doi: 10.1158/2326-6066.CIR-19-0229.
- Gandolfi, S. *et al.* (2021) “OAB-019: CRISPR screens with single-cell transcriptome readout reveal potential mechanisms of response to natural killer cell treatment in multiple myeloma,” *Clinical Lymphoma Myeloma and Leukemia*. Elsevier, 21, hal. S12–S13.
- Ghazawi, F. M. *et al.* (2019) “Uveal melanoma incidence trends in Canada: a national comprehensive population-based study,” *The British journal of ophthalmology*. England, 103(12), hal. 1872–1876. doi: 10.1136/bjophthalmol-2018-312966.
- Gooden, M. *et al.* (2011) “HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes,” *Proceedings of the National Academy of Sciences*. National Acad Sciences, 108(26), hal. 10656–10661.
- Guo, Y. *et al.* (2021) “Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis,” *European Journal of Immunology*. Wiley Online Library, 51(10), hal. 2513–2521.

- Hall, T. van *et al.* (2017) "NKG2A checkpoint receptor expression on tumor-infiltrating CD8+ T cells restrains efficacy of immunotherapy," *Cancer Research*. AACR, 77(13\_Supplement), hal. 2999.
- van Hall, T. *et al.* (2019) "Monalizumab: inhibiting the novel immune checkpoint NKG2A.," *Journal for immunotherapy of cancer*. England, 7(1), hal. 263. doi: 10.1186/s40425-019-0761-3.
- Heistein, J. B., Acharya, U. dan Mukkamalla, S. K. R. (2023) "Malignant Melanoma.," in. Treasure Island (FL).
- Highton, A. J. *et al.* (2020) "High Metabolic Function and Resilience of NKG2A-Educated NK Cells.," *Frontiers in immunology*. Switzerland, 11, hal. 559576. doi: 10.3389/fimmu.2020.559576.
- Hoerster, K. *et al.* (2021) "HLA class I knockout converts allogeneic primary NK cells into suitable effectors for 'Off-the-Shelf' immunotherapy," *Frontiers in immunology*. Frontiers Media SA, 11, hal. 586168.
- Huang, R. Y.-C. *et al.* (2021) "Higher-Order Structure Characterization of NKG2A/CD94 Protein Complex and Anti-NKG2A Antibody Binding Epitopes by Mass Spectrometry-Based Protein Footprinting Strategies.," *Journal of the American Society for Mass Spectrometry*. United States, 32(7), hal. 1567–1574. doi: 10.1021/jasms.0c00399.
- Hussein, M. R. *et al.* (2006) "Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions.," *Journal of clinical pathology*. England, 59(3), hal. 316–324. doi: 10.1136/jcp.2005.028860.
- Jhunjhunwala, S., Hammer, C. dan Delamarre, L. (2021) "Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion," *Nature Reviews Cancer*. Nature Publishing Group UK London, 21(5), hal. 298–312.
- Kamiya, T. *et al.* (2019) "Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.," *The Journal of clinical investigation*. United States, 129(5), hal. 2094–2106. doi: 10.1172/JCI123955.
- Lee, H. *et al.* (2021) "Targeting NK Cells to Enhance Melanoma Response to Immunotherapies," *Cancers*. doi: 10.3390/cancers13061363.
- Lunemann, S. *et al.* (2019) "Human liver-derived CXCR6(+) NK cells are predominantly educated through NKG2A and show reduced cytokine production.," *Journal of leukocyte biology*. England, 105(6), hal. 1331–1340. doi: 10.1002/JLB.1MA1118-428R.
- Maibach, F. *et al.* (2020) "Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma," 11(September), hal. 1–20. doi: 10.3389/fimmu.2020.02105.
- Malmberg, K.-J. *et al.* (2002) "IFN- $\gamma$  protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism," *The Journal of clinical investigation*. Am Soc Clin Investig, 110(10), hal. 1515–1523.
- Marques, S. C. (2016) "Review Article MITOSES IN CUTANEOUS MALIGNANT MELANOMAS: Relevance in the prognosis,"

*Universidade de Lisboa, Faculdade de Medicina de Lisboa Clínica  
Universitária de Dermatologia.*

- Mauny, M. P. (2017) “Ekspresi mRNA Gen PDL-1, PD-1 dan Imunoterapi pada Kanker Kandung Kemih,” in *Ekspresi mRNA Gen PDL-1, PD-1 dan Imunoterapi pada Kanker Kandung Kemih*, hal. 1–30.
- McWilliams, E. M. *et al.* (2016) “Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.,” *Oncoimmunology*. United States, 5(10), hal. e1226720. doi: 10.1080/2162402X.2016.1226720.
- Miller, R. R. *et al.* (2008) “Association between interleukin-6 and lower extremity function after hip fracture--the role of muscle mass and strength,” *Journal of the American Geriatrics Society*. 2008/04/11, 56(6), hal. 1050–1056. doi: 10.1111/j.1532-5415.2008.01708.x.
- Mingari, M. C., Pietra, G. dan Moretta, L. (2019) “Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board.,” *Trends in immunology*. England, 40(2), hal. 83–85. doi: 10.1016/j.it.2018.12.009.
- van Montfoort, N. *et al.* (2018) “NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.,” *Cell*. United States, 175(7), hal. 1744–1755.e15. doi: 10.1016/j.cell.2018.10.028.
- Morinaga, T. *et al.* (2022) “Evaluation of HLA-E expression combined with natural killer cell status as a prognostic factor for advanced gastric cancer,” *Annals of Surgical Oncology*. Springer, 29(8), hal. 4951–4960.
- Mukherji, B. (2013) “Immunology of melanoma.,” *Clinics in dermatology*. United States, 31(2), hal. 156–165. doi: 10.1016/j.clindermatol.2012.08.017.
- Neagu, M. (2012) “The immune system--a hidden treasure for biomarker discovery in cutaneous melanoma.,” *Advances in clinical chemistry*. United States, 58, hal. 89–140. doi: 10.1016/b978-0-12-394383-5.00011-4.
- Nguyen, S. *et al.* (2009) “HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytotoxicity after haplo-mismatched hematopoietic SCT.,” *Bone marrow transplantation*. England, 43(9), hal. 693–699. doi: 10.1038/bmt.2008.380.
- Ott, P. A. (2019) “Intralesional Cancer Immunotherapies.,” *Hematology/oncology clinics of North America*. United States, 33(2), hal. 249–260. doi: 10.1016/j.hoc.2018.12.009.
- Pasaribu ET, Setiaji K, Rinonce HT, Azhar RY, Wahyono A, Pasaribu ET. Clinical and pathological profile of skin melanoma in Dr. Sardjito Hospital, Yogyakarta, Indonesia. *Eur J Surg Oncol*. 2019:e137. Available from. <https://doi.org/10.1016/j.ejso.2018.10.466>.
- Pathak, S. dan Zito, P. M. (2023) “Clinical Guidelines for the Staging, Diagnosis, and Management of Cutaneous Malignant Melanoma.,” in. *Treasure Island (FL)*.
- Pegram, H. J. *et al.* (2011) “Activating and inhibitory receptors of natural killer cells,” *Immunology & Cell Biology*, 89(2), hal. 216–224. doi: <https://doi.org/10.1038/icb.2010.78>.
- Pitcovski, J. *et al.* (2017) “Melanoma antigens and related immunological



- markers.," *Critical reviews in oncology/hematology*. Netherlands, 115, hal. 36–49. doi: 10.1016/j.critrevonc.2017.05.001.
- Plougastel, B., Jones (Corbett-Jones), T. dan Trowsdale, J. (1996) "Genomic structure, chromosome location, and alternative splicing of the human NKG2A gene," *Immunogenetics*, 44, hal. 286–291. doi: 10.1007/BF02602558.
- Quiying, Ma., Huinan Suo. *et al.* (2020) "Prognostic significance of tumor size for primary invasive cutaneous melanoma: A population-based study, 2004–2016",
- Rähni, A. *et al.* (2022) "Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted immunotherapies," *Communications Medicine*, 2(1). doi: 10.1038/s43856-022-00114-7.
- Ram, D. R. *et al.* (2019) "Simian Immunodeficiency Virus Infection Modulates CD94(+) (KLRD1(+)) NK Cells in Rhesus Macaques.," *Journal of virology*. United States, 93(16). doi: 10.1128/JVI.00731-19.
- Raulet, D. H. dan Guerra, N. (2009) "Oncogenic stress sensed by the immune system: role of natural killer cell receptors," *Nature Reviews Immunology*. Nature Publishing Group UK London, 9(8), hal. 568–580.
- Rosenthal, R. *et al.* (2019) "Neoantigen-directed immune escape in lung cancer evolution.," *Nature*. England, 567(7749), hal. 479–485. doi: 10.1038/s41586-019-1032-7.
- Saginala, K. *et al.* (2021) "Epidemiology of Melanoma.," *Medical sciences (Basel, Switzerland)*. Switzerland, 9(4). doi: 10.3390/medsci9040063.
- Saputro, R. D. *et al.* (2021) "Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma.," *BMC research notes*. England, 14(1), hal. 206. doi: 10.1186/s13104-021-05623-7.
- Saputro, R. R., Junaidi, A. dan Saputra, W. A. (2022) "Klasifikasi Penyakit Kanker Kulit Menggunakan Metode Convolutional Neural Network (Studi Kasus: Melanoma).," *Journal of Dinda : Data Science, Information Technology, and Data Analytics*, 2(1), hal. 52–57. doi: 10.20895/dinda.v2i1.349.
- Shahbaz, S. *et al.* (2021) "The Quality of SARS-CoV-2-Specific T Cell Functions Differs in Patients with Mild/Moderate versus Severe Disease, and T Cells Expressing Coinhibitory Receptors Are Highly Activated.," *Journal of immunology (Baltimore, Md. : 1950)*. United States, 207(4), hal. 1099–1111. doi: 10.4049/jimmunol.2100446.
- Sheffer, M. *et al.* (2021) "Genome-scale screens identify factors regulating tumor cell responses to natural killer cells," *Nature Genetics*. Nature Publishing Group US New York, 53(8), hal. 1196–1206.
- Sheu, B.-C. *et al.* (2005) "Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.," *Cancer research*. United States, 65(7), hal. 2921–2929. doi: 10.1158/0008-5472.CAN-04-2108.

- Suman, S. dan Markovic, S. N. (2023) "Melanoma-derived mediators can foster the premetastatic niche: crossroad to lymphatic metastasis," *Trends in Immunology*, 44(9), hal. 724–743. doi: <https://doi.org/10.1016/j.it.2023.07.002>.
- Sun, C. *et al.* (2017) "High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer.," *Oncoimmunology*. United States, 6(1), hal. e1264562. doi: 10.1080/2162402X.2016.1264562.
- Sung, H. *et al.* (2021) "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.," *CA: a cancer journal for clinicians*. United States, 71(3), hal. 209–249. doi: 10.3322/caac.21660.
- Tarhini, A. *et al.* (2019) "Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA.," *Journal of comparative effectiveness research*. England, 8(7), hal. 461–473. doi: 10.2217/ce-2019-0003.
- Vetter, C. S. *et al.* (2000) "Expression of CD94/NKG2 Subtypes on Tumor-Infiltrating Lymphocytes in Primary and Metastatic Melanoma," *Journal of Investigative Dermatology*, 114(5), hal. 941–947. doi: <https://doi.org/10.1046/j.1523-1747.2000.00958.x>.
- Wang, X., Xiong, H. dan Ning, Z. (2022) "Implications of NKG2A in immunity and immune-mediated diseases," *Frontiers in Immunology*, 13(August), hal. 1–11. doi: 10.3389/fimmu.2022.960852.
- Wu, Z. *et al.* (2020) "HLA-E expression in diffuse glioma: relationship with clinicopathological features and patient survival.," *BMC neurology*. England, 20(1), hal. 59. doi: 10.1186/s12883-020-01640-4.
- Yazdi, M. T. *et al.* (2016) "The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma," *Oncotarget*. Impact Journals, LLC, 7(3), hal. 3477.
- Zaghi, E. *et al.* (2019) "Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy.," *Journal of leukocyte biology*. England, 105(6), hal. 1243–1251. doi: 10.1002/JLB.MR0718-300R.
- Z. Zhou, C. Zhang, J. Zhang, Z. Tian, J. Zimmer, Macrophages help NK cells to attack tumor cells by stimulatory NKG2D ligand but protect themselves from NK killing by inhibitory ligand Qa-1, *PLoS One* 7 (5) (2012) e36928.